Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Immunovant, Inc. from 31 Mar 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Immunovant, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Mar 2019 to 30 Jun 2025.
  • Immunovant, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 30 Jun 2025 was $115,059,000, a 53% decline year-over-year.
  • Immunovant, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $78,606,000, a 70% decline from 2023.
  • Immunovant, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $258,833,000.
  • Immunovant, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $117,285,000, a 225% decline from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Immunovant, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $115,059,000 -$39,699,000 -53% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2026 Q1
Q2 2024 $75,360,000 -$28,788,000 -62% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2026 Q1
Q2 2023 $46,572,000 +$20,040,000 +30% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2025 Q1
Q2 2022 $66,612,000 -$45,471,000 -215% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2024 Q1
Q2 2021 $21,141,000 -$200,849,000 -112% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2023 Q1
Q2 2020 $179,708,000 +$182,737,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q1
Q2 2019 $3,029,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q1

Immunovant, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $78,606,000 -$180,227,000 -70% 01 Apr 2024 31 Mar 2025 10-K 29 May 2025 2025 FY
2023 $258,833,000 +$376,118,000 01 Apr 2023 31 Mar 2024 10-K 29 May 2025 2025 FY
2022 $117,285,000 -$210,956,000 -225% 01 Apr 2022 31 Mar 2023 10-K 29 May 2025 2025 FY
2021 $93,671,000 -$205,904,000 -69% 01 Apr 2021 31 Mar 2022 10-K 22 May 2023 2023 FY
2020 $299,575,000 +$205,989,000 +220% 01 Apr 2020 31 Mar 2021 10-K 08 Jun 2022 2022 FY
2019 $93,586,000 +$86,601,000 +1240% 01 Apr 2019 31 Mar 2020 10-K 01 Jun 2021 2020 FY
2018 $6,985,000 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.